Tonix Pharmaceuticals Files 8-K
Ticker: TNXP · Form: 8-K · Filed: May 21, 2025 · CIK: 1430306
Sentiment: neutral
Topics: sec-filing, 8-k, routine-update
Related Tickers: TNXP
TL;DR
TNXP filed an 8-K, likely routine. No major news.
AI Summary
Tonix Pharmaceuticals Holding Corp. filed an 8-K on May 21, 2025, reporting on other events and financial statements. The filing does not disclose specific new material events or financial figures but serves as a routine update.
Why It Matters
This filing indicates Tonix Pharmaceuticals is providing updates to the SEC, which could relate to ongoing business activities or financial reporting requirements.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain information that inherently increases risk.
Key Players & Entities
- Tonix Pharmaceuticals Holding Corp. (company) — Registrant
- May 21, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of Incorporation
- 001-36019 (identifier) — Commission File Number
- 26-1434750 (identifier) — IRS Employer Identification No.
- 26 Main Street, Chatham, New Jersey 07928 (address) — Principal executive offices
- (862) 904-8182 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing for Tonix Pharmaceuticals Holding Corp. on May 21, 2025?
The filing is a Current Report on Form 8-K, reporting on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits, with the earliest event reported as May 21, 2025.
What is Tonix Pharmaceuticals Holding Corp.'s state of incorporation and IRS Employer Identification Number?
The company is incorporated in Nevada and its IRS Employer Identification Number is 26-1434750.
Where are Tonix Pharmaceuticals Holding Corp.'s principal executive offices located?
The principal executive offices are located at 26 Main Street, Chatham, New Jersey 07928.
What is the Commission File Number for Tonix Pharmaceuticals Holding Corp.?
The Commission File Number is 001-36019.
Does this 8-K filing disclose any specific new material events or financial results?
The provided text of the filing does not detail specific new material events or financial results, indicating it may be a routine or procedural filing.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 21, 2025 regarding Tonix Pharmaceuticals Holding Corp. (TNXP).